Bio/Pharma Business

The company announced it is creating a new Primary Care global business unit and a China & Emerging Markets unit.

More than 120 healthcare organizations plan to bring competition to generic drug market.

Novartis will sell selected portions of its Sandoz United States portfolio to Aurobindo Pharma USA for $900 million in cash, plus $100 million in potential earn-outs.

Alcami and the University of North Carolina Wilmington received a grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals to prepare students for careers in pharmaceutical sciences.

Girish Malhotra argues in CPhI Annual Report that shorter approval times and financial incentives are needed to promote manufacturing improvements.

Preliminary survey results rank the United States, Germany, and Japan as tier-one nations for bioprocessing performance and potential.

Pharmaceutical scientist association announces upcoming term’s board of directors.

The Alliance for Regenerative Medicine’s (ARM) report highlights major trends and metrics from the 2018 second quarter in the regenerative medicines sector.

Boehringer Ingelheim joins Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, and Imperial Innovations to form a partnership for developing a new gene therapy to treat cystic fibrosis.

Frustrated by slow market adoption, Gottlieb maps out new plan for biosimilar competition.

Waters’ acquisition of Prosolia’s DESI technology boosts its mass spectrometry imaging portfolio.

In launching FDA’s Biosimilar Action Plan, Gottlieb takes innovator companies to task for delaying competitive biosimilar products.

AbbVie will grant Mylan license to launch a biosimilar to AbbVie’s Humira.

Pfizer creates separate business units for innovator medicines, generic drugs, and consumer products.

Biogen will pay Samsung BioLogics approximately $700 million to increase its stake in Samsung Bioepis to approximately 49.9%.

The pharma major intends to spinoff Alcon as a stand-alone eye-care devices company.

Catalent’s acquisition of Juniper Pharmaceuticals further expands its early development capabilities.

After 30 years of biologic-drug advances, the industry and patients still have a lot to learn.

Strategic restructuring is designed to position GE Healthcare as a pure-play healthcare company.

GW Research’s Epidiolex, which treats two forms of epilepsy, receives FDA’s approval; spurs FDA reminders about unapproved products.

The three-year collaboration will focus on developing vaccines for up to five infectious disease pathogens.

Intelligent manufacturing and environmental policies are key trends at P-MEC 2018.

The India Expo Mart in Delhi will host CPhI and P-MEC India with expected attendance of 50,000.

The gene therapy company is expected to invest $55 million in a new manufacturing facility that will produce therapies for rare neurological genetic diseases.

Allergan will buy a potential depression treatment from Aptinyx.

The new company will develop proprietary RNA-based therapeutics and will provide broad lentiviral development and manufacturing expertise and support.

Internationalization and regulatory reform are driving growth and investment China.

Valerius Biopharma will use Catalent’s GPEx technology to produce cell lines for biosimilar drugs.

The BioIndustry Association has called on the British government to introduce a new venture capital fund structure that will enable the public to invest in the United Kingdom’s biotech revolution.

Barriers impede biosimilar market entry into the United States despite the Biologics Price Competition and Innovation Act.